Beam Therapeutics BEAM Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $164.01M+158% | $139.74M+120% | $55.7M-84.1% | $60.27M-82.9% | $63.58M-82.4% | ||
| $415.33M+8.8% | $409.62M+11.4% | $411.79M+1.4% | $396.28M-3.8% | $381.56M-9.7% | ||
| $120.31M+6.7% | $113.82M+2.1% | $110.2M-12.6% | $109.97M-12.0% | $112.74M-6.1% | ||
| $535.63M+8.4% | $523.44M+9.3% | $521.99M-1.9% | $506.25M-5.7% | $494.3M-8.9% | ||
| -$371.62M+13.7% | -$383.69M+7.7% | -$466.29M— | -$445.98M— | -$430.72M— | ||
| -226.6%+451pp | -274.6%+380pp | -837.1%— | -739.9%— | -677.5%— | ||
| $306.58M+591% | $304.64M+684% | $52.58M+29.9% | $48.34M+12.9% | $44.36M-8.2% | ||
| —— | —— | -$413.7M— | -$397.64M— | -$386.4M— | ||
| —— | —— | -$4.42— | -$4.49— | -$4.60— | ||
| -$349.25M+14.5% | -$361.4M+8.2% | -$444.22M— | -$423.99M— | -$408.7M— | ||
| -212.9%+430pp | -258.6%+361pp | -797.5%— | -703.5%— | -642.8%— | ||
| -$371.62M+13.7% | -$383.69M+7.7% | -$466.29M— | -$445.98M— | -$430.72M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Beam Therapeutics's revenue?
- Beam Therapeutics (BEAM) generated $164.0M in revenue over the trailing twelve months, up 158.0% year over year.
- Is Beam Therapeutics profitable?
- Beam Therapeutics is not currently profitable: it reported a net loss of $417.7M over the trailing twelve months, a -742.7% net margin.
- What is Beam Therapeutics's earnings per share?
- Beam Therapeutics's diluted EPS over the trailing twelve months is $-4.24.
- Where does Beam Therapeutics's income statement data come from?
- Every line is extracted from Beam Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
